Boston Trust Walden Corp Has $46.01 Million Stake in U.S. Physical Therapy, Inc. (NYSE:USPH)

Boston Trust Walden Corp lowered its stake in U.S. Physical Therapy, Inc. (NYSE:USPH - Free Report) by 2.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 518,675 shares of the company's stock after selling 13,138 shares during the period. Boston Trust Walden Corp owned approximately 3.43% of U.S. Physical Therapy worth $46,012,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of USPH. KBC Group NV boosted its position in shares of U.S. Physical Therapy by 68.6% in the third quarter. KBC Group NV now owns 774 shares of the company's stock valued at $66,000 after acquiring an additional 315 shares during the period. Pacer Advisors Inc. bought a new stake in U.S. Physical Therapy in the 4th quarter valued at about $113,000. First Horizon Advisors Inc. grew its position in shares of U.S. Physical Therapy by 25.1% during the 3rd quarter. First Horizon Advisors Inc. now owns 1,486 shares of the company's stock worth $126,000 after purchasing an additional 298 shares in the last quarter. International Assets Investment Management LLC grew its position in shares of U.S. Physical Therapy by 8,414.8% during the 3rd quarter. International Assets Investment Management LLC now owns 2,299 shares of the company's stock worth $195,000 after purchasing an additional 2,272 shares in the last quarter. Finally, Sugar Maple Asset Management LLC bought a new position in shares of U.S. Physical Therapy during the third quarter worth approximately $212,000.

U.S. Physical Therapy Price Performance

Shares of U.S. Physical Therapy stock traded down $0.76 during trading on Friday, reaching $86.97. 83,883 shares of the company's stock were exchanged, compared to its average volume of 86,891. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.78 and a current ratio of 1.78. U.S. Physical Therapy, Inc. has a 1-year low of $76.18 and a 1-year high of $113.63. The company has a market cap of $1.31 billion, a P/E ratio of 92.52, a PEG ratio of 3.65 and a beta of 1.48. The firm's 50-day moving average price is $91.29 and its 200 day moving average price is $88.51.

Insider Transactions at U.S. Physical Therapy

In other news, Director Bernard A. Harris, Jr. sold 2,000 shares of U.S. Physical Therapy stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $92.95, for a total transaction of $185,900.00. Following the sale, the director now directly owns 16,726 shares of the company's stock, valued at approximately $1,554,681.70. This trade represents a 10.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Carey P. Hendrickson sold 516 shares of the business's stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $96.25, for a total value of $49,665.00. Following the sale, the chief financial officer now owns 20,469 shares in the company, valued at approximately $1,970,141.25. This trade represents a 2.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.70% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on USPH. Barrington Research reiterated an "outperform" rating and issued a $108.00 price target on shares of U.S. Physical Therapy in a research note on Thursday, November 21st. JMP Securities initiated coverage on U.S. Physical Therapy in a research report on Monday, December 16th. They set an "outperform" rating and a $113.00 target price for the company. Bank of America upgraded U.S. Physical Therapy from a "neutral" rating to a "buy" rating and raised their price target for the stock from $100.00 to $115.00 in a research report on Monday, December 16th. JPMorgan Chase & Co. upped their price objective on shares of U.S. Physical Therapy from $117.00 to $120.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 3rd. Finally, Citizens Jmp raised shares of U.S. Physical Therapy to a "strong-buy" rating in a report on Monday, December 16th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $114.00.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.